Similarly, the ribonucleotide reductase subunit RRM2B was considered to be associated with advanced stage III-IV tumors that have better survival than early stage I-II tumors, and its expression was associated with better survival prognosis in CRC patients [63]. Here, RRM2B is linked to colorectal carcinoma.